Clinical trials: ASCVD, active
Atherosclerotic Cardiovascular Disease (ASCVD), Secondary Prevention
Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients
Elderly patients with cardiovascular disease face a high risk of both thrombotic and bleeding events when receiving antithrombotic therapy.
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Secondary Prevention, Cardiovascular Diseases
- Trial name
- LAPIS (NCT07542860)
- Where
- China
- Volunteers
- 5,448 people
- Sponsor
- Peking University First Hospital
Metabolic Syndrome, Hypertension
Development and Multicenter Validation of an AI-Based Remote Photoplethysmography (rPPG) Facial Scan for Multimodal Health Assessment
The goal of this observational study is to learn if a non-contact facial scan using artificial intelligence (AI) can be used to check health status in adults living in urban areas such as Jakarta.
- Conditions
- Metabolic Syndrome, Hypertension, Diabetes (DM), Tachycardia
- Trial name
- NCT07491978
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tarumanagara University
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease (ASCVD)
Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
This study will evaluate the effectiveness and safety of combining two different types of PCSK9 inhibitors, inclisiran and alirocumab, in patients with high cardiovascular risk who are unable to tolerate statins.
- Trial name
- PCSK9-DUO (NCT07581808)
- Testing
- Inclisiran, Alirocumab
- Where
- Slovenia
- Volunteers
- 60 people
- Sponsor
- University Medical Centre Ljubljana
Lipoprotein Disorder
A Study of DII235 in Adults With Elevated Lipoprotein(a)
The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).
- Trial name
- NCT07235046
- Testing
- DII235, Saline
- Where
- 63 sites in United States, China and 2 more
- Volunteers
- 234 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this…
- Trial name
- STaRT (NCT06858332)
- Testing
- Atorvastatin, Simvastatin, Rozuvastatin
- Where
- 20 sites in Russia
- Volunteers
- 2,382 people
- Sponsor
- Novartis Pharmaceuticals
Pre Diabetes, ASCVD
Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)
This study is to evaluating the impact of low-intensity statin plus ezetimibe versus high-intensity statin therapy on risk of new-onset diabetes mellitus in patients with atherosclerotic cardiovascular disease who have…
- Trial name
- NCT05579626
- Testing
- high-intensity statin arm, low-intensity statin plus ezetimibe
- Where
- 31 sites in South Korea
- Volunteers
- 4,000 people
- Sponsor
- Seung-Whan Lee, M.D., Ph.D.
Prostate Cancer
ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation…
- Trial name
- NCT05879913
- Testing
- Coronary CT Angiography (CCTA)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Indiana University
ASCVD, Diabetes
Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus
The AVOID-DM trial is a multicenter, prospective, randomized study comparing the risk of new-onset diabetes mellitus (DM) between two cholesterol-lowering strategies in patients with prediabetes and established atherosclerotic…
- Conditions
- ASCVD, Diabetes, Statin
- Trial name
- NCT06767774
- Testing
- Combination therapy, High intensity statin monotherapy
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Korea University Anam Hospital
Hyperlipemia, Mixed, ASCVD
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management
A 400-patient U.S.-based single-center Quality Improvement Initiative in the form of a randomized controlled trial focused on the feasibility of implementation of this electronic alert-based CDS (EPIC BPA) based on LDL-C values.
- Trial name
- LDL-ALERT (NCT05088759)
- Testing
- Alert
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
No Condition
CLAiR Pivotal Study
This is a multi-site, observational clinical study to validate the performance of the CLAiR AI software in identifying elevated atherosclerotic cardiovascular disease (ASCVD) risk from retinal (eye) images obtained from two…
- Trial name
- NCT06808334
- Testing
- CLAIR
- Where
- United States
- Volunteers
- 942 people, healthy volunteers welcome
- Sponsor
- Toku Eyes Ltd
Hypercholesterolemia
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
A multicenter study to evaluate safety and efficacy of inclisiran in Asian patients with ASCVD or ASCVD high risk and elevated LDL-C
- Trial name
- NCT04765657
- Testing
- inclisiran sodium
- Where
- 45 sites in China, Singapore and 2 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerosis, Cardiovascular Disease
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
- Conditions
- Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
- Trial name
- HEART-3 (NCT07839936)
- Testing
- VERVE-102
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Verve Therapeutics, Inc.
Gene Polymorphism, ASCVD
NPC1L1 Gene Polymorphism and the Efficacy and Safety of Hybutimibe
Significant individual differences may lead to differences in patients' responses to drug therapy and lead to an increased incidence of adverse reactions.
- Trial name
- NCT06641661
- Testing
- Hybutimibe 10mg QD
- Volunteers
- 1,000 people
- Sponsor
- Qianfoshan Hospital
ASCVD, LDL-C
Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?
The goal of this implementation trial is to learn if providing education to doctors and patients who have had a heart event works to prevent future heart problems. The main questions it aims to answer are: 1.
- Trial name
- T2T (NCT06471036)
- Testing
- Care Champion Intervention
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Duke University
Familial Hypercholesterolemias, Atherosclerotic Cardiovascular Disease (ASCVD)
Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)
The goal of this study (interventional clinical research not involving a health product) is to assess the prevalence of subclinical coronary atherosclerosis diagnosed by coronary CT angiography in heart failure patients in…
- Trial name
- ATHERO-FH (NCT06960902)
- Testing
- Coronary CT scan with CAC score measurement
- Where
- 9 sites in France
- Volunteers
- 600 people
- Sponsor
- Nantes University Hospital
Atherosclerotic Cardiovascular Disease, Older Patients
LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)
To determine whether treating to an LDL-C target of 25 to <70 mg/dL is superior to an LDL-C target of 70 to <100 mg/dL with respect to major cardiovascular events (cardiovascular death, myocardial infarction, stroke…
- Conditions
- Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol
- Trial name
- NCT05765370
- Testing
- Achieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL, Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL
- Where
- China
- Volunteers
- 4,200 people
- Sponsor
- China National Center for Cardiovascular Diseases
ASCVD, Diabetes
Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease
The goal of the ADHERE-ASCVD study is to evaluate and optimize patient-facing messaging strategies to improve statin refill and adherence among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes.
- Trial name
- ADHERE-ASCVD (NCT07522645)
- Testing
- SMS (Initial Outreach), Secure Portal Message (Initial Outreach), Non-secure Email (Initial Outreach)
- Where
- United States
- Volunteers
- 22,000 people
- Sponsor
- Kaiser Permanente
Atherosclerosis Cardiovascular Disease, ASCVD
Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD.
- Conditions
- Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
- Trial name
- NCT07303777
- Testing
- ABP-745 Dose A, ABP-745 Dose B, ABP-745 Dose C
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 200 people
- Sponsor
- Atom Therapeutics Co., Ltd
Wearable Device, Cardiovascular Disease
HEARTS in Sync + CardioWatch 287-2
The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync.
- Conditions
- Wearable Device, Cardiovascular Disease, ASCVD Management, CHF - Congestive Heart Failure
- Trial name
- NCT07322510
- Testing
- Remote Patient Monitoring with Corsano CardioWatch 287-2
- Where
- Canada
- Volunteers
- 216 people
- Sponsor
- Nova Scotia Health Authority
Atherosclerotic Cardiovascular Disease (ASCVD), Hypertension
Evaluation of an Integrated, Digital, Nurse-led, Remote Monitoring Care Pathway for Cardiovascular Risk Management
The goal of this observational study is to evaluate the implementation of a structured, digital, nurse-led, remote monitoring care pathway for cardiovascular risk management (CVRM).
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Hypertension, Dyslipidemia
- Trial name
- TELE-CVRM (NCT07208331)
- Where
- Netherlands
- Volunteers
- 750 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)